Search

ENPNewswire-November 4, 2024--Lilly to Present Results from Phase 3 EMBER-3 study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer [...]

INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader [...]

Reuters - EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection - 15/11/2024 The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's [...]

Financial Times - AbbVie shares tumble after schizophrenia drug disappoints - 11/11/2024 Shares in AbbVie tumbled after the drugmaker revealed that an experimental treatment for schizophrenia, the main drug purchased [...]

Financial Times - Jeff Smith, the activist picking a fight with Covid hero Pfizer - 26/10/2024 Taking to the stage this week in front of an annual gathering of activist [...]

PMLiVE - Roche's Alecensa receives NICE recommendation to treat ALK-positive lung cancer - 21/10/2024 Roche's Alecensa (alectinib) has been recommended by the National Institute of Health and Care Excellence (NICE) [...]

China Daily - Global Edition - AstraZeneca expanding R&D pipeline in China - 14/10/2024 In an interview with China Daily, Sharon Barr, executive vice-president of biopharmaceuticals R&D at AstraZeneca, said [...]

China Daily - AstraZeneca announces plans for new innovations for China - 30/9/2024 United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and [...]

Financial Times - AstraZeneca drug fails to extend lives of breast cancer patients - 23/9/2024 Latest setback for Dato-DXd comes after disappointing results in lung cancer treatment earlier this month. [...]

Clinical Trials Arena - Bristol Myers Squibb's CAMZYOS offers benefits in oHCM trial - 2/9/2024 Bristol Myers Squibb (BMS) has unveiled new long-term follow-up results from the EXPLORER-LTE cohort of [...]

ENPNewswire-August 9, 2024--Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 08082024 - INDIANAPOLIS - Eli Lilly and Company (NYSE: [...]

SEATTLE: Atossa Therapeutics, Inc. has issued the following news release: Atossa Therapeutics, Inc. (Nasdaq: ATOS) ('Atossa' or the 'Company') today announced protocol changes in the previously initiated study to evaluate [...]

ENPNewswire-May 1, 2024--Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 30042024 - INDIANAPOLIS - Eli [...]

Financial Times - AstraZeneca threatens to move UK vaccine manufacturing to US - 23/8/2024 AstraZeneca has warned it could relocate its vaccine manufacturing site on Merseyside to Philadelphia amid a [...]

The Pharmaletter - UK must get ready for new cell and gene therapies, says ABPI - 19/8/2024 The UK's National Health Service (NHS) got off to a good start with [...]

Agreement to provide Verzenio (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of [...]

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2023. 'Lilly had [...]

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding [...]

ENPNewswire-October 23, 2023--Eli Lilly and Company - Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio's Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- [...]

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% [...]

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib; a CDK4/6 inhibitor), Retevmo(r) [...]

ENPNewswire-October 9, 2023--Lilly Announces Details of Presentations at ESMO Congress 2023 (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 06102023 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today announced that [...]

INDIANAPOLIS, Oct. 6, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(abemaciclib; a CDK4/6 inhibitor), Retevmo(selpercatinib; a rearranged during transfection [RET] inhibitor), [...]

ENPNewswire-September 20, 2023--Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors (C)2023 [...]

ENPNewswire-June 5, 2023--Lilly Highlights Verzenio and Jaypirca) Data at 2023 ASCO Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 02062023 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today [...]

Novartis breast cancer drug Kisqali cut the risk of recurrence by 25% in early-stage breast cancer, positioning the Swiss drugmaker to win new patients and challenge strong rival Eli Lilly. [...]